<DOC>
	<DOCNO>NCT00520403</DOCNO>
	<brief_summary>This single arm study ass efficacy safety Avastin combination interferon alfa-2a vinblastine first line treatment patient metastatic renal cell cancer . Patients receive Avastin ( 15mg/kg iv ) every 3 week , interferon alfa-2a 3 time weekly ( 3 Mio IU sc escalate 18 Mio sc ) vinblastine ( 0.1mg/kg iv ) every 3 week . The anticipated time study treatment tumor progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Standard Therapy Patients With Metastatic Renal Cell Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; metastatic renal cell cancer predominantly clear cell type ; &gt; =1 measurable lesion . prior treatment chemotherapy , cytokine tyrosine kinase inhibitor therapy metastatic renal cell cancer ; ongoing recent need full therapeutic dose anticoagulant chronic daily treatment aspirin ( &gt; 325mg/day ) ; clinically significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>